Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv March 16 (Reuters) - Rhythm Pharmaceuticals (RYTM.O), opens new tabsaid on Monday its experimental obesity drug in patients with rare genetic conditions did not meet the main goal of a late-stage trial. Shares of the Boston-based company fell over 7% in extended trading. Purchase Licensing Rights Business Kone i ...